Predicting Psychotic Relapse Using Speech-Based Early Detection
Recruiting · NCT06978894 · Observational (researchers observe without assigning treatment) · Lead sponsor: Douglas Mental Health University Institute
View the official record on ClinicalTrials.gov →What this trial is about
Psychotic disorders, including schizophrenia and affective psychosis, are severe mental health conditions marked by recurrent episodes that contribute to long-term disability. Relapses, characterized by the re-emergence of psychotic symptoms after remission, are a critical factor in the progression of these disorders, increasing risks such as suicide, cognitive impairment, and unemployment. This study aims to develop a novel, speech-based digital model to predict relapses in individuals with psychosis. Building on previous research into language abnormalities in schizophrenia, the study will employ a longitudinal design across Early Psychosis Intervention (EPI) clinics in Ontario and Quebec to advance relapse prediction
Who can take part
Inclusion criteria
- Age must be 16 years and older
- Diagnosis must meet DSM-5 criteria for psychotic disorders, including schizophrenia, schizoaffective disorder, or related conditions
- Fluency in English or French
- Must be currently receiving treatment through an EPI program
Exclusion criteria
- Severe comorbid speech or language disorders (e.g., aphasia)
- Primary diagnosis of non-psychotic disorders
- Inability to provide consent or complete assessments
Where it is running
3 locations listed.
- Robarts Research Institute - London, Ontario, Canada
- Douglas Mental Health University Institute - Montreal, Quebec, Canada
- Vitam - Québec, Quebec, Canada